Valuation Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147.82 USD | +0.30% |
|
+2.01% | -19.85% |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12,295 | 18,771 | 10,941 | 12,249 | 9,520 | 7,239 | - | - |
| Change | - | 52.67% | -41.71% | 11.95% | -22.28% | -23.96% | - | - |
| Enterprise Value (EV) 1 | 14,046 | 21,196 | 13,418 | 14,619 | 11,565 | 9,407 | 9,031 | 8,878 |
| Change | - | 50.9% | -36.69% | 8.95% | -20.89% | -18.66% | -4% | -1.7% |
| P/E ratio | 34.3x | 48.9x | 22.7x | 25.9x | 931x | 32.7x | 25.5x | 22x |
| PBR | 5.82x | 7.38x | 3.68x | 3.41x | 2.75x | 2.14x | 1.96x | 1.88x |
| PEG | - | 8.8x | 0.9x | -9.44x | -9.5x | 0x | 0.9x | 1.4x |
| Capitalization / Revenue | 4.2x | 5.3x | 2.75x | 2.97x | 2.35x | 1.86x | 1.82x | 1.78x |
| EV / Revenue | 4.8x | 5.99x | 3.37x | 3.54x | 2.86x | 2.41x | 2.28x | 2.18x |
| EV / EBITDA | 20x | 24.1x | 13.5x | 14.4x | 11.6x | 9.94x | 9.22x | 8.47x |
| EV / EBIT | 24x | 28.6x | 16.1x | 17.4x | 14.3x | 12.4x | 11.4x | 10.5x |
| EV / FCF | 37x | 39.8x | 45.5x | 40x | 23.1x | 25x | 21x | 19.2x |
| FCF Yield | 2.71% | 2.51% | 2.2% | 2.5% | 4.34% | 4% | 4.77% | 5.21% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.2 | 7.6 | 9.48 | 9.22 | 0.2 | 4.512 | 5.785 | 6.708 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,924 | 3,540 | 3,976 | 4,129 | 4,050 | 3,898 | 3,967 | 4,070 |
| EBITDA 1 | 701.3 | 879.5 | 990.9 | 1,013 | 996.1 | 946.9 | 979.8 | 1,049 |
| EBIT 1 | 585 | 742.1 | 834 | 838.8 | 805.9 | 756.8 | 794.9 | 845.3 |
| Net income 1 | 364.3 | 391 | 486.2 | 474.6 | 10.3 | 219.4 | 272.8 | 312.6 |
| Net Debt 1 | 1,751 | 2,425 | 2,477 | 2,370 | 2,046 | 2,169 | 1,792 | 1,639 |
| Reference price 2 | 247.17 | 371.96 | 215.04 | 238.78 | 186.16 | 147.38 | 147.38 | 147.38 |
| Nbr of stocks (in thousands) | 49,743 | 50,464 | 50,879 | 51,297 | 51,136 | 49,116 | - | - |
| Announcement Date | 17/02/21 | 16/02/22 | 22/02/23 | 14/02/24 | 19/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 32.66x | 2.41x | 9.94x | -.--% | 7.24B | ||
| 38.8x | 5.65x | 19.8x | 0.87% | 48.77B | ||
| 164.91x | 5.56x | 90.29x | -.--% | 30.55B | ||
| 20.75x | 2.45x | 10.38x | -.--% | 26.84B | ||
| 41x | 8.41x | 24.75x | 0.45% | 25.49B | ||
| 22.29x | - | - | 1.16% | 12.34B | ||
| 15.83x | 1.8x | 9.04x | -.--% | 11.71B | ||
| -43.26x | 9.57x | 2216.4x | -.--% | 11.37B | ||
| -41.11x | 15.6x | -48.52x | -.--% | 10.61B | ||
| Average | 27.98x | 6.43x | 291.51x | 0.28% | 20.55B | |
| Weighted average by Cap. | 44.89x | 6.02x | 170.86x | 0.37% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- CRL Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition